Bendamustine
Treanda · Alkylator
Tumor lysis-mediated AKI is the principal risk; TMA is rare.
PRETMALYTE
ModerateOpen →
Telomerase inhibitor
Imetelstat
Rytelo · IMET
A first-in-class telomerase inhibitor for low-risk MDS — kidney concern is mainly tumor-lysis/cytopenia, not direct toxicity.
MildTelomerase inhibitor · approved 2024
Lower-risk myelodysplastic syndromes (transfusion-dependent anemia)
Signature kidney injury
Prerenal / Hemodynamic AKI
No established direct nephrotoxicity. In IMerge the dominant toxicities were cytopenias (thrombocytopenia, neutropenia); renal injury was not a defining adverse event. Tumor-lysis-type metabolic risk is theoretical and most relevant with high disease burden, not a quantified rate in lower-risk MDS.
Source: Platzbecker et al., Lancet 2023
Mechanism of kidney injury
No characterized intrinsic tubular/glomerular injury. Potential renal stress is indirect: rapid cytoreduction could in principle produce tumor-lysis metabolic derangements (hyperuricemia and hyperphosphatemia with intratubular urate/calcium-phosphate crystal deposition and AKI), and cytopenia-related complications (infection, bleeding, transfusion-related volume shifts) can drive prerenal AKI.
Clinical presentation
Generally bland renal picture; if tumor lysis occurs, rising uric acid/phosphate/potassium with creatinine elevation. Otherwise creatinine changes track intercurrent illness and volume status.
Onset
Any tumor-lysis-type risk would be early after initiation; otherwise no defined renal onset.
Reversibility
Reversible
Anticancer mechanism
13-mer lipid-conjugated oligonucleotide that binds the RNA template (hTR) of telomerase via Watson-Crick base pairing, competitively inhibiting telomerase enzymatic activity and shortening telomeres in malignant clones. Approved for transfusion-dependent anemia in lower-risk myelodysplastic syndromes (MDS) refractory to or ineligible for erythropoiesis-stimulating agents.
Management
Supportive; standard tumor-lysis prophylaxis/treatment (IV hydration, allopurinol or rasburicase for hyperuricemia) if metabolic derangements appear, and correction of prerenal factors. No drug-specific renal antidote; intrinsic nephrotoxicity has not been described.
Risk factors
- Higher disease burden / rapid cytoreduction (TLS risk)
- Pre-existing CKD or hyperuricemia
- Cytopenia-related infection or bleeding with volume depletion
- Concurrent nephrotoxins
Prevention
- Hydration and TLS monitoring in higher-burden disease
- Routine creatinine, uric acid and electrolyte checks
- Manage cytopenias and infections promptly
Note · 2024 first-in-class approval; renal literature is essentially absent. The tumor-lysis/prerenal framing is conservative class reasoning, supported by general onconephrology/TLS reviews rather than imetelstat-specific renal data.
Clinical depth
Renal dose adjustment
No dedicated renal dose adjustment is established in lower-risk MDS labeling. As an oligonucleotide, elimination is largely via nuclease metabolism/tissue distribution rather than glomerular filtration; mild-moderate renal impairment is not expected to require change. No data in severe impairment or dialysis.
Dialyzability & ESKD dosing
Not characterized; large protein-bound oligonucleotides are generally not appreciably removed by hemodialysis. No ESKD dosing guidance.
Differential diagnosis
Distinguish tumor-lysis AKI (urate/phosphate elevation, early) from prerenal AKI of cytopenia-related infection/bleeding; structural drug nephrotoxicity is not a described entity for this agent.
Monitoring
- CBC with platelets frequently (cytopenias are the dominant toxicity)
- Creatinine, uric acid, phosphate, potassium early in higher-burden patients (TLS screen)
- Volume status with transfusions and intercurrent illness
Key trials & series
- IMerge phase 3 (Platzbecker, Lancet 2023) — registrational, cytopenia-dominant safety
Clinical pearls
- The renal worry at initiation is tumor lysis, not a tubulopathy — screen labs early in higher-burden disease.
- Cytopenias dominate the safety profile; renal events are incidental and indirect.
- First-in-class 2024 agent — renal data are essentially absent; reason from class and TLS principles.
Where it strikes
Nephron segments
Vasculature / Endothelium
Glomerular & peritubular capillaries
Injury signatures
Prerenal / Hemodynamic AKIElectrolyte Wasting
Evidence
5 peer-reviewed references. Citation metadata via PubMed / NLM.
LandmarkImetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial.Platzbecker U et al. · Lancet 2023 · PMID 38048786Pivotal trial; toxicity is cytopenia-dominant with no renal signal, supporting the qualitative renal assessment.PMIDImetelstat, a novel, first-in-class telomerase inhibitor: Mechanism of action, clinical, and translational science.Lennox AL et al. · Clin Transl Sci 2024 · PMID 39555853Mechanism/clinical pharmacology review establishing the drug class and its pharmacology (oligonucleotide, non-renal clearance).PMIDAcute Kidney Injury in Patients With Cancer: A Review of Onconephrology.Gudsoorkar P et al. · Adv Chronic Kidney Dis 2021 · PMID 35190106Onconephrology review of tumor-lysis-related AKI — the basis for the conservative metabolic/prerenal framing.PMIDTumor Lysis Syndrome.Barbar T et al. · Adv Chronic Kidney Dis 2021 · PMID 35190110Focused TLS review (urate/phosphate intratubular injury, rasburicase/allopurinol, hydration) underpinning prophylaxis at cytoreduction.PMIDTumour lysis syndrome.Howard SC et al. · Nat Rev Dis Primers 2024 · PMID 39174582Authoritative TLS primer detailing pathophysiology, risk stratification and prevention.
Related agents
Other agents sharing the same signature kidney injury.